Suggestions
Julie Clauss
Highly experienced Business Unit leader
Julie Clauss is a highly experienced business leader currently serving as a Strategic Advisory Board Member at Odyssey Therapeutics.1 Her professional background includes:
Career Highlights
- Founder & Board Member at Aptabridge Therapeutics since September 20221
- Board Member at French Tech Boston since January 20211
- Vice President Gene Therapy Platform Lead at Ultragenyx Pharmaceutical Inc. from August 2021 to September 20221
- Vice President, Head of R&D Operations at IPSEN BIOSCIENCE, INC. from 2018 to 20201
Education
Julie holds an MIT Sloan Fellows MBA from the MIT Sloan School of Management, which she completed in 2021.1
Expertise
Julie Clauss has demonstrated excellent capabilities in:
- Defining business unit vision and strategy
- Managing global R&D operations
- Implementing critical R&D projects and initiatives
- Leading large teams and managing substantial budgets
- Driving integrated planning cultures within R&D organizations
Location
She is based in Cambridge, Massachusetts, United States.1
It's worth noting that while Julie Clauss has a significant role at Odyssey Therapeutics, her current LinkedIn profile does not specifically list her as Chief Operating Officer. Her most recent position related to Odyssey Therapeutics is listed as Strategic Advisory Board Member.1
Highlights
I’m happy to share that I’m starting a new position as Chief Operating Officer at Odyssey Therapeutics!
I am deeply honored to have the privilege of serving on the French Tech Boston Board and contributing as one of the organizers for this significant event for the 10 years of the French Tech community. I extend my sincere gratitude to Mr. Consul Mustafa SOYKURT for hosting this event at the French consulate. During the event, I had the pleasure of presenting key insights into the remarkable journey of French Tech and its pivotal role in shaping the technology landscape, particularly here in Boston, where we proudly represent over 100 startups and boast a membership of over 130 dedicated individuals. I want to express my heartfelt appreciation to all the members who attended this dynamic event and, most importantly, to our esteemed speakers who shared their genuine testimonials and invaluable lessons from their entrepreneurial ventures, Jeremy Jawish CEO and Cofounder of Shift Technologies, Kévin Alessandri Cofounder and CTO of Treefrog Therapeutics, Patrick Tricoli US CEO of Nanobiotix. Thank you for the other FT Boston board members who contributed to the success of this event Audrey Philippot Dahan, Charlotte Turnier (Servan), Joseph Péteul , Chris Hote, Julien L. Pham, MD, MPH , Zena Sfeir Gehchan, Francois Silvain, Aymeric Vigneras, Jerome Windsor It's truly a testament to the strength and unity of the French Tech community, and I am excited about the innovative opportunities and collaborative efforts that lie ahead. Thank you all for being a part of this inspiring occasion.
